Skip to main content
Ajooni Biotech Limited logo

Ajooni Biotech Limited — Investor Relations & Filings

Ticker · AJOONI ISIN · INE820Y01021 LEI · 335800OAKJWKHF49O339 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 562 across all filing types
Latest filing 2025-06-26 Major Shareholding Noti…
Country IN India
Listing National Stock Exchange of India AJOONI

About Ajooni Biotech Limited

https://www.ajoonibiotech.com

Ajooni Biotech Limited specializes in the production and distribution of animal healthcare solutions and nutritional supplements. The company focuses on the livestock sector, offering a comprehensive range of products including compounded cattle feed, mineral mixtures, and specialized supplements formulated to enhance milk productivity and overall animal health. Its portfolio features calcium supplements, liver tonics, and digestive aids designed to meet the specific nutritional needs of dairy animals. The company utilizes research-driven formulations and quality-controlled manufacturing processes to provide effective solutions for livestock management. By prioritizing animal welfare and productivity, it supports the operational efficiency of dairy farming through scientifically developed nutritional interventions.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, which pertains to reporting on substantial acquisition of shares or encumbrance status by promoters. It is a regulatory compliance filing related to shareholding disclosures rather than a financial report, earnings release, or management discussion. The document is short (2801 characters) and is a formal notification to the stock exchange. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or confirmations regarding significant share ownership levels or encumbrances by promoters or major shareholders.
2025-06-26 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of quarterly and annual financial results for Q4 FY25 and 12M FY25, including key financial highlights such as Total Income, EBITDA, and PAT with year-on-year growth percentages. It also contains management commentary on the financial performance and business developments. The presence of audited financials and comprehensive financial data for a quarter and full fiscal year indicates this is a financial report for a period shorter than a full fiscal year (quarterly and annual combined). However, since it includes both quarterly and annual data but focuses on the quarter and year-end results with detailed financial metrics and management discussion, it aligns best with an Interim / Quarterly Report (IR) rather than a brief earnings release or just an announcement. The document length (6138 characters) and content confirm it is a substantive financial report rather than a short announcement or press release. Therefore, the classification is Interim / Quarterly Report (IR). FY 2025
2025-05-31 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement on deviation or variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It specifically addresses the utilization of proceeds from a Right Issue for the quarter ended March 31, 2025. The document includes detailed tables showing the original and modified allocation of funds, utilization amounts, and confirms no deviation or variation in the use of funds. It is signed by the Managing Director and mentions review by the Audit Committee and Board. The content is regulatory compliance related to fund utilization reporting rather than a full financial report or earnings release. It is not an announcement of a report but a formal regulatory filing required by SEBI. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-05-26 English
Outcome of Board Meeting
Regulatory Filings
2025-05-26 English
Outcome of Board Meeting
Regulatory Filings
2025-05-26 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, which pertains to the declaration of no encumbrance over shares by promoters and promoter groups for the financial year ended March 31, 2025. This type of disclosure relates to changes or confirmations in substantial shareholdings or related regulatory compliance. It is not a financial report, audit, or management discussion, nor is it an announcement of voting results or dividend. The document is a regulatory compliance filing related to shareholding disclosures under SEBI regulations. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ). The document length is under 5,000 characters and contains direct disclosure information, not just an announcement of a report, so it is not RPA or RNS. Confidence is high due to clear reference to SEBI regulation and shareholding disclosures.
2025-04-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.